

DEPARTMENT OF THE AIR FORCE 59TH MEDICAL WING (AETC) JOINT BASE SAN ANTONIO - LACKLAND TEXAS

6 MAY 2016

MEMORANDUM FOR ST

ATTN: SHARON LAWSON

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

- 1. Your paper, entitled <u>Hyperbaric Normothermic Perfusion Mitigates Reperfusion Injury in Porcine VCA</u> presented at/published to <u>Association of Surgeons Great Britain and Ireland 11-13 May 2016</u> with MDWI 41-108, and has been assigned local file #16191.
- 2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.
- 3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are 59 MDW staff member, we can forward your request for funds to the designated wing POC.
- 4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC Director, Clinical Investigations & Research Support

linda Steet-Goodwin

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

INSTRUCTIONS USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

- 1. The author must complete page two of this form:
 - a. In Section 2, add the funding source for your study [e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SG5 O&M); SG5 R&D;
 Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP); Grants; etc.]
 - b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.
- 2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.
- 3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protoco! Title" box.
- 4. Attach a copy of your abstract, paper, poster and other supporting documentation.
- Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.
- 6. On page 2, have either your unit commander, program director or immediate supervisor:
 - a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.
- Submit your completed form and all supporting documentation to the CRD for processing (59crdpubspres@us.af.mil). If you have any questions or concerns, please contact the 59 CRD/ Publications and Presentations Section at 292-7141 for assistance.
- 8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.
- Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. Note: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.
- 10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DITC). See 59 MDW/ 41-108, Presentation and Publication of Medical and Technical Papers, for additional information.
- NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:
 - "The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"
- NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:
 - "The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AFI 40-402."
- NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401_IP:
 - "The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS						
1. TO: CLINICAL RESEARCH 2. FROM: (Au	thor's Name, Rank, Grad	e. Office Symbol)			4. PROTOCOL NUMBER:	
	on, CTR, 59MDW ST		X YES		FWH20150008A	
Thust be submitted for	 PROTOCOL TITLE: (NOTE: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.) 					
Evaluation of Tissue Preservation Method and Device for 8 hours for Gracilis Myocutaneous Flap Transplant in a Swine model (Sus scrofa do						
6. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED:						
Hyperbaric normothermic perfusion mitigates reperfusion injury in porcine VCA						
7. FUNDING RECEIVED FOR THIS STUDY? YES NO FUNDING SOURCE: AFMSA/59 MDW ST						
8. DO YOU NEED FUNDING SUPPORT FOR PUBLICATION PURPOSES: YES NO						
-	s 🛛 NO					
10. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.? YES NO NOTE: If the answer is YES then attach a copy of the Agreement to the Publications/Presentations Request Form.						
11. MATERIAL IS FOR: DOMESTIC RELE	EASE X FOREIGN RE	LEASE				
CHECK APPROPRIATE BOX OR BOXES FOR APPROVAL WITH THIS REQUEST. ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED. 11a. PUBLICATION/JOURNAL (List intended publication/journal.)						
11b. PUBLISHED ABSTRACT (List Intended journal.)						
L. FUBLISHED ABSTRACT (List intended journal.)						
11c. POSTER (To be demonstrated at meeting: name of meeting, city, state, and date of meeting.)						
11d. PLATFORM PRESENTATION (At a	ivilian institutions; name	of masting state and data of me	ation)			
Association of Surgeons of Great Bri	tain and Ireland/ 11-13	R May 2016	eung.)			
11e. OTHER (Describe: name of meeting, city, state, and date of meeting.)						
12. EXPECTED DATE WHEN YOU WILL NEED THE CRD TO SUBMIT YOUR CLEARED PRESENTATION/PUBLICATION TO DTIC						
NOTE: All publications/presentations are n	equired to be placed in th	e Defense Technical Information	Center (DTIC).			
DATE						
May 10, 2016						
13. 59 MDW PRIMARY POINT OF CONTACT	(Last Name, First Name,	M.I., email)		14. DUTY	PHONE/PAGER NUMBER	
C P 10 1			2105394			
15. AUTHORSHIP AND CO-AUTHOR(S) List I	n the order they will appe	ar in the manuscript				
LAST NAME, FIRST NAME AND M.I.	GRADE/RANK	SQUADRON/GROUP/OF	FICE SYMBOL	INST	ITUTION (If not 59 MDW)	
Primary/Corresponding Author Sharon Lawson	CTR					
b.		59MDW ST RESTOR				
Lin Wang	O-3	59MDW ST RESTOR				
Renford Cindass	O-3	59MDW ST RESTOR				
Kevin Wu	CTR	59MDW ST RESTOR				
e. Michael R Davis	O-5	59MDW ST RESTOR				
f.						
I CERTIFY ANY HUMAN OR ANIMAL RESEARCH RELATED STUDIES WERE APPROVED AND PERFORMED IN STRICT ACCORDANCE WITH 32 CFR 219, AFMAN 40-401_IP, AND 59 MDWI 41-108. I HAVE READ THE FINAL VERSION OF THE ATTACHED MATERIAL AND CERTIFY THAT IT IS AN ACCURATE MANUSCRIPT FOR PUBLICATION AND/OR PRESENTATION.						
16. AUTHOR'S PRINTED NAME, RANK, GRAD		17. AUTHOR'S SIGNA	TURE	-50	18. DATE	
Sharon Lawson, CTR	٢	_			April 26, 2016	
19. APPROVING AUTHORITY'S PRINTED NAME, RANK, TITLE 20. APPROVING AUTHORITY'S SIGNATURE 21. DATE					21. DATE	
Michael R Davis, Lt Col, Director-RESTOR, Deputy Commander April 26, 2016					April 26, 2016	
59 MDW FORM 3039, 20160218 PREVIOUS EDITIONS CURRENTLY IN USE CAN BE USED Page 2 of 3 Pages Prescribed by 59 MDW 41-108 PREVIOUS EDITIONS CURRENTLY IN USE CAN BE USED Page 2 of 3 Pages						

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS						
1st ENDORSEMENT (59 MDW/SGVU Use Only)	AND ADDRESS DESCRIPTION DESCRIPTION OF A LINE AND A LONG AND A LON	IDED				
TO: Clinical Research Division 59 MDW/CRD Contact 292-7141 for email instructions. 22. DATE RECEIVED 4/26/2016	23. ASSIGNED PROCESSING REQUEST FILE NUM 16191	IBEK				
24. DATE REVIEWED	25. DATE FORWARDED TO 502 ISG/JAC					
28. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANG	ES: NO YES If yes, give date.	N/A				
27. COMMENTS APPROVED DISAPPROVED .						
28. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	29. REVIEWER SIGNATURE	30. DATE				
2nd ENDORSEMENT (502 ISG/JAC Use Only)						
31. DATE RECEIVED						
34. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	35. REVIEWER SIGNATURE	36. DATE				
3rd ENDORSEMENT (59 MDW/PA Use Only)		1				
37. DATE RECEIVED	38. DATE FORWARDED TO 59 MDW/SGVU					
20160506	20160506					
39. COMMENTS APPROVED (In compliance with security and policy review directives.) The presentation is approved for release.						
40. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	41. REVIEWER SIGNATURE	42. DATE				
Ellis, Michael, E-5		20160506				
4th ENDORSEMENT (59 MDW/SGVU Use Only)		D DIGADOS CITE				
43. DATE RECEIVED 44. SENIOR AUTHOR NOTIFIED BY PHONE OF APPROVAL OR DISAPPROVAL YES NO COULD NOT BE REACHED LEFT MESSAGE						
45. COMMENTS APPROVED DISAPPROVED						
46. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	47. REVIEWER SIGNATURE	48. DATE				



Hyperbaric normothermic perfusion mitigates reperfusion injury in porcine VCA

SD Lawson, LC Wang, R Cindass, K Wu, MR Davis

Research Fellow, RESTORTM Program, General Surgery Resident, UTHSCSA Sharon Lawson, MD

RESTORTM Program, 59th Medical Wing, JBSA Lackland AFB





Disclaimer

The opinions or assertions contained herein are the private views of the author and are not to be construed as official or as reflecting the views of the Department of Defense. The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended



Background

- Vascularized Composite Allotransplantation can reconstruct any non-visceral tissue defect
- VCA is a clinical reality for military trauma patients









- The requirement for long term systemic immunosuppression limits it's application to only a few highly motivated patients
- Treatment failures, morbidity and mortality associated with VCA means that it remains an experimental modality1
- Reconstructive surgeons are divided on the utility of VCA2
- Further research is mandatory before the field can move forward

¹Tullius, S., Uehara, H., Yang, X., & Edtinger, K. (2014). Current status of vascularized composite tissue allotransplantation. Burns & Trauma, 2(2), 53. doi:10.4103/2321-3868.130184


²Bertrand, A. A., Sen, S., Otake, L. R., & Lee, G. K. (2014). Changing attitudes toward hand allotransplantation among North American hand surgeons. Annals of Plastic Surgery, 72 Suppl 1, S56–60





- Exacerbation of cellular/tissue injury after an ischemic insult with re-establishment of blood flow
- Generation of oxidative stress
- Microvascular obstruction/thrombosis
- Neutrophil activation
- Complement activation
- Release of anaphylotoxins
- associated with increased rates and severity of acute rejection Increasing severity of IRI at time of transplant in solid organs

Effects of Ischemia and Reperfusion Injury on Long-Term Graft Function L.R. Requião-Moura, M. de Souza Durão, E.J. Tonato, A.C. Carvalho Matos, K.S. Ozaki, N.O.S. Câmara, and A. Pacheco-Silva








Left Hind Limb

Gracilis Muscle






Methods





Methods

Exposure of Neck Vessels







Intervention




Warm ex vivo perfusion device –

- Experiments since the 1960s have showed ability to sustain animals with low hematocrit in hyperbaric environment
- Ex vivo perfusion of transplant organs highly desirable

Boerema, I., Meyne, N. G., Brummelkamp, W. H., Bouma, S., Mensch, M. H., Kamermans, F., & STERN, H. M. (1960). Life without blood]. Nederlands tijdschrift voor geneeskunde, 104, 949.

D, M. A. C. M., D, E. K. M., D, X. X. P., D, D. M. K. M., Jenni, H., c, E. G. D. H., et al. (2011). Preservation of Amputated Extremities by Extracorporeal Blood Perfusion; a Feasibility Study in a Porcine Model. Journal of Surgical Research, 171(1), 291–299. doi:10.1016/j.jss.2010.01.040



- Model development showed that 5 hours of cold ischemia was not tolerable to muscle flap (n=5)
 - Control group = 3 hours cold ischemia with UW solution (n=5)
- Intervention group = 7 hours warm ischemia (37C) (n=8)



Results



Gracilis auto-transplants –

Treatment

Ct

Exp

No Muscle

No Muscle

Hour 0

Necrosis

Necrosis


80% with severe muscle necrosis


Hour 3


Hour 7

60% with no muscle necrosis,

40% with minimal necrosis









Summary

- ischemic period tolerable to tissue composites compared to the Hyperbaric normothermic perfusion reliably extends the current gold standard
- Ischemic and cold-preservation injuries are mitigated
- This has application in VCA and solid organ transplantation
- expand donor pool
- superior matches for transplant candidates



Future direction

End point to be extended to 21 days to further characterize graft survival.

agents like H₂S and antioxidants as well as locally-applied graft Application of MSCs and combination of ischemia reperfusion immunosuppression in allotransplantation

Forelimb allotransplantation





Acknowledgements



- Lin Wang, MD USA Institute of Surgical Research/ 59MDW Science and Technology Office
- J.R. Spencer 59MDW Science and Technology Office
- Anton Fries, MRCS Royal Centre for Defence Medicine
- Capt Carole Villamaria, MD USAF, UTHSCSA
- Raul Corpus, MPH 59MDW Science and Technology Office







Thank you



